RU2009107030A - Комбинированная терапия - Google Patents
Комбинированная терапия Download PDFInfo
- Publication number
- RU2009107030A RU2009107030A RU2009107030/15A RU2009107030A RU2009107030A RU 2009107030 A RU2009107030 A RU 2009107030A RU 2009107030/15 A RU2009107030/15 A RU 2009107030/15A RU 2009107030 A RU2009107030 A RU 2009107030A RU 2009107030 A RU2009107030 A RU 2009107030A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- acceptable salt
- vla
- use according
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 claims abstract 32
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims abstract 18
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims abstract 18
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims abstract 14
- 238000000034 method Methods 0.000 claims abstract 10
- MNQBPRHHZPXCKZ-ZDCRTTOTSA-N (2s)-2-[[(2s)-1-(3,5-dichlorophenyl)sulfonylpyrrolidine-2-carbonyl]amino]-4-[[(2s)-4-methyl-2-[methyl-[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoyl]amino]butanoic acid Chemical group CN([C@@H](CC(C)C)C(=O)NCC[C@H](NC(=O)[C@H]1N(CCC1)S(=O)(=O)C=1C=C(Cl)C=C(Cl)C=1)C(O)=O)C(=O)CC(C=C1)=CC=C1NC(=O)NC1=CC=CC=C1C MNQBPRHHZPXCKZ-ZDCRTTOTSA-N 0.000 claims abstract 7
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical group C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims abstract 7
- 229960002169 plerixafor Drugs 0.000 claims abstract 7
- 210000004027 cell Anatomy 0.000 claims abstract 6
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 230000003211 malignant effect Effects 0.000 claims abstract 4
- 210000005259 peripheral blood Anatomy 0.000 claims abstract 4
- 239000011886 peripheral blood Substances 0.000 claims abstract 4
- 210000000130 stem cell Anatomy 0.000 claims abstract 4
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims abstract 3
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims abstract 3
- 206010025323 Lymphomas Diseases 0.000 claims abstract 3
- 239000000556 agonist Substances 0.000 claims abstract 3
- 238000002617 apheresis Methods 0.000 claims abstract 2
- 238000002512 chemotherapy Methods 0.000 claims abstract 2
- 238000012258 culturing Methods 0.000 claims abstract 2
- 230000003394 haemopoietic effect Effects 0.000 claims abstract 2
- 208000032839 leukemia Diseases 0.000 claims abstract 2
- 230000001483 mobilizing effect Effects 0.000 claims abstract 2
- 238000001959 radiotherapy Methods 0.000 claims abstract 2
- CWJJHESJXJQCJA-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical group C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CC=N1 CWJJHESJXJQCJA-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83529006P | 2006-08-02 | 2006-08-02 | |
| US60/835,290 | 2006-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009107030A true RU2009107030A (ru) | 2010-09-10 |
Family
ID=38997866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009107030/15A RU2009107030A (ru) | 2006-08-02 | 2007-08-02 | Комбинированная терапия |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100003224A1 (https=) |
| EP (1) | EP2068868A2 (https=) |
| JP (1) | JP2009545620A (https=) |
| CN (1) | CN101495115A (https=) |
| AR (1) | AR063470A1 (https=) |
| AU (1) | AU2007281090A1 (https=) |
| BR (1) | BRPI0714799A2 (https=) |
| CA (1) | CA2659463A1 (https=) |
| IL (1) | IL196556A0 (https=) |
| MX (1) | MX2009001272A (https=) |
| RU (1) | RU2009107030A (https=) |
| WO (1) | WO2008017025A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004020462A1 (ja) | 2002-08-27 | 2004-03-11 | Fujii, Nobutaka | Ｃｘｃｒ４拮抗薬およびその用途 |
| CA2673719C (en) * | 2006-12-21 | 2018-07-24 | Biokine Therapeutics Ltd. | T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery |
| US9427456B2 (en) | 2009-06-14 | 2016-08-30 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
| WO2012034194A1 (en) * | 2010-09-17 | 2012-03-22 | Antisense Therapeutics Ltd | Method for mobilizing stem and/or progenitor cells |
| US9682078B2 (en) | 2011-03-18 | 2017-06-20 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
| RU2638802C2 (ru) | 2011-05-16 | 2017-12-15 | Джензим Корпорейшн | Применение антагонистов cxcr4 |
| WO2012174522A1 (en) * | 2011-06-16 | 2012-12-20 | Children's Medical Center Corporation | Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment |
| US9439942B2 (en) | 2012-04-24 | 2016-09-13 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
| SG11201704756YA (en) * | 2014-12-12 | 2017-07-28 | Commw Scient Ind Res Org | Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist |
| IL274572B2 (en) | 2015-07-16 | 2024-01-01 | Biolinerx Ltd | Compositions and methods for treating cancer |
| CN109310733A (zh) | 2016-02-23 | 2019-02-05 | 百欧林纳克斯有限公司 | 治疗急性骨髓性白血病的方法 |
| JP7034085B2 (ja) * | 2016-04-08 | 2022-03-11 | サイロス ファーマシューティカルズ， インコーポレイテッド | Ａｍｌ及びｍｄｓの治療のためのｒａｒａアゴニスト |
| WO2018085574A2 (en) * | 2016-11-02 | 2018-05-11 | Washington University | Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof |
| TWI734027B (zh) * | 2017-09-18 | 2021-07-21 | 泰宗生物科技股份有限公司 | 用於治療癌症之組合物 |
| CN111712262A (zh) * | 2017-12-06 | 2020-09-25 | 美真达治疗公司 | 用于动员造血干细胞和祖细胞的给药方案 |
| US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| DE69433301T2 (de) * | 1993-06-08 | 2004-09-09 | Smithkline Beecham Corp. | Methoden zur erhöhung der biologischen aktivität von chemokinen |
| US6447766B1 (en) * | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
| US5510332A (en) * | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| ATE180843T1 (de) * | 1994-08-19 | 1999-06-15 | Akzo Nobel Nv | Zelluloselösungen und hieraus hergestellte produkte |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| US5968546A (en) * | 1997-05-16 | 1999-10-19 | Baur; Marcus | Keratinocyte culture from precursor cells |
| HUP0102255A3 (en) * | 1998-05-28 | 2001-12-28 | Biogen Idec Ma Inc Cambridge | Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| US6750348B1 (en) * | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| GEP20053477B (en) * | 1999-08-13 | 2005-03-25 | Biogen Inc | Cell Adhesion Inhibitors and Pharmaceutical Compositions Containing Them |
| DE60042030D1 (de) * | 1999-12-17 | 2009-05-28 | Genzyme Corp | Chemokinrezeptor-bindende heterocyclische verbindungen |
| US6835731B2 (en) * | 2000-09-15 | 2004-12-28 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| PT1317451E (pt) * | 2000-09-15 | 2006-12-29 | Anormed Inc | Compostos heterocíclicos que se ligam a receptores de quimioquinas |
| CA2419224A1 (en) * | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| AU2002211393B2 (en) * | 2000-09-29 | 2007-06-28 | Anormed Inc. | Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof |
| EP1613613B1 (en) * | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| AU2004232361A1 (en) * | 2003-04-22 | 2004-11-04 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7501518B2 (en) * | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
| EP1708703A4 (en) * | 2003-12-11 | 2008-04-09 | Anormed Inc | CHEMOKIN RECEPTOR BINDING COMPOUNDS |
| CN1930127B (zh) * | 2004-03-15 | 2012-11-21 | 阿诺麦德股份有限公司 | 用于合成cxcr4拮抗剂的方法 |
| JP2008509928A (ja) * | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | 前駆／幹細胞を動員するためのケモカインの組み合わせ |
| US7825088B2 (en) * | 2005-04-25 | 2010-11-02 | The Cbr Institute For Biomedical Research, Inc. | Methods for the treatment of multiple myeloma |
-
2007
- 2007-08-02 AU AU2007281090A patent/AU2007281090A1/en not_active Abandoned
- 2007-08-02 US US12/375,987 patent/US20100003224A1/en not_active Abandoned
- 2007-08-02 BR BRPI0714799-6A patent/BRPI0714799A2/pt not_active Application Discontinuation
- 2007-08-02 AR ARP070103423A patent/AR063470A1/es not_active Application Discontinuation
- 2007-08-02 WO PCT/US2007/075064 patent/WO2008017025A2/en not_active Ceased
- 2007-08-02 CN CNA200780028588XA patent/CN101495115A/zh active Pending
- 2007-08-02 EP EP07813695A patent/EP2068868A2/en not_active Withdrawn
- 2007-08-02 CA CA002659463A patent/CA2659463A1/en not_active Abandoned
- 2007-08-02 JP JP2009523051A patent/JP2009545620A/ja not_active Withdrawn
- 2007-08-02 MX MX2009001272A patent/MX2009001272A/es unknown
- 2007-08-02 RU RU2009107030/15A patent/RU2009107030A/ru not_active Application Discontinuation
-
2009
- 2009-01-15 IL IL196556A patent/IL196556A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101495115A (zh) | 2009-07-29 |
| EP2068868A2 (en) | 2009-06-17 |
| WO2008017025A2 (en) | 2008-02-07 |
| WO2008017025A3 (en) | 2008-10-09 |
| JP2009545620A (ja) | 2009-12-24 |
| BRPI0714799A2 (pt) | 2013-05-21 |
| MX2009001272A (es) | 2009-02-11 |
| AU2007281090A1 (en) | 2008-02-07 |
| US20100003224A1 (en) | 2010-01-07 |
| IL196556A0 (en) | 2009-11-18 |
| CA2659463A1 (en) | 2008-02-07 |
| AR063470A1 (es) | 2009-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009107030A (ru) | Комбинированная терапия | |
| RU2009108289A (ru) | Комбинированная терапия | |
| JP2009545620A5 (https=) | ||
| Pusic et al. | Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells | |
| JP2010507567A5 (https=) | ||
| Fruehauf et al. | It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement. | |
| Liesveld et al. | Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells | |
| ES2756336T3 (es) | Métodos que modulan el efecto inmunorregulador de las células madre | |
| Shao et al. | Transplantation of bone marrow–derived mesenchymal stem cells after regional hepatic irradiation ameliorates thioacetamide-induced liver fibrosis in rats | |
| JP2023085370A5 (https=) | ||
| Mohty et al. | In and out of the niche: perspectives in mobilization of hematopoietic stem cells | |
| US20140154207A1 (en) | Kit containing stem cells and cytokines for use in attenuating immune responses | |
| Isidori et al. | Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| RU2009100930A (ru) | Лекарственные средства для стимуляции роста гемопоэтических стволовых клеток | |
| CO6311007A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas | |
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| Marquez-Curtis et al. | The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes | |
| CN105934155A (zh) | 在调节疼痛和/或纤维化中使用脂肪组织来源的细胞的方法 | |
| Goker et al. | Optimizing mobilization strategies in difficult-to-mobilize patients: the role of plerixafor | |
| EA200500757A1 (ru) | Новое применение декстрансульфата | |
| Leung et al. | Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies | |
| Jin et al. | Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100803 |